With a one year PEG ratio of 533.05, Pacira BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.43% of US stocks.
The price/operating cash flow metric for Pacira BioSciences Inc is higher than 95.38% of stocks in our set with a positive cash flow.
With a price/sales ratio of 6.29, Pacira BioSciences Inc has a higher such ratio than 80.38% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Pacira BioSciences Inc are YELP, AYX, GORO, KALA, and VIVE.
PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.
Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.
PCRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for PCRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Pacira BioSciences Inc ranked in the 12th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Pacira BioSciences Inc ended up being:
87% of the company's capital comes from equity, which is greater than 71.6% of stocks in our cash flow based forecasting set.
The weighted average cost of capital for the company is 9. This value is greater than 73.04% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Pacira BioSciences Inc? See LGND, BLFS, LMNX, STAA, and RGEN.
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Pacira BioSciences' (PCRX) Exparel (bupivacaine liposome injectable suspension) for the treatment of postoperative pain.A final decision from the European Commission usually takes ~60 days....
Pacira BioSciences, Inc. (PCRX) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants Zach Sachar – Piper Sandler Randall Stanicky – RBC Capital Markets...
PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 3276818. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-4...
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Pacira BioSciences, Inc. (PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $300.0 million aggregate principal amount of notes. Pacira also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $52.5 million aggregate principal amount of notes.